Posted on April 20, 2015
BOTOX® (onabotulinumtoxinA) was approved by the FDA in 2010 for the debilitating neurological condition upper limb spasticity. Now, it has been approved also for use in both the flexor pollicis longus and the adductor pollicis, muscles used for flexing the thumb and adducting the thumb. Patients 18 years and older may be injected with the prescription medicine, which is to be used in conjunction with physical therapy. Almost 2 million Americans have upper body spasticity, which can limit their ability to perform simple tasks.
The approval of expansion of treatment with BOTOX® (onabotulinumtoxinA) is based on 2 studies that clearly showed the statistical significance of the neurotoxin vs placebo. Also approved was the increase in dose for the treatment of upper limb spasticity. The BOTOX ® (onabotulinumtoxinA) is injected into muscles to decrease stiffness in the elbow, wrist, and fingers only.
To read more about this, please go here.